Darunavir (Prezista)

Published August 09, 2006; Updated October 19, 2011
Susa Coffey, MD
http://hivinsite.ucsf.edu/InSite?page=ar-03-10
Selected References
4. Darunavir [package insert]. East Bridgewater, NJ: Tibotec Therapeutics: 2010; update forthcoming.
10. De Meyer S, A Hill, De Baere I, et al. Effect of Baseline Susceptibility and On-treatment Mutations on TMC114 and Control PI Efficacy: Preliminary Analysis of Data from PI-experienced Patients from POWER 1 and POWER 2. In: Program and abstracts of the 13th Conference on Retroviruses and Opportunistic Infections; February 5-9, 2006; Denver. Abstract 157.
11. De Meyer S, Vangeneugden T, Lefebvre E, van Marck H, Azijn H, De Baere I, van Baelen B, de Béthune MP. Response to TMC114 is Based on Genotypic/Phenotypic Resistance: POWER 1/2/3 pooled analysis. 8th International Congress on Drug Therapy in HIV Infection, Glasgow, UK, 12-16 November 2006. Poster 196.